Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: Cozaar, Cozaar Comp, Cozaar®, Cozaar® Comp, Cozaar® Comp Forte, Fortzaar Comp Forte, Forzaar Comp Forte, Klomentan, Klomentan Comp, Losamyl Comp, Losarstad, Losarstad Comp, Losartan Actavis, Losartan Aurobindo, Losartan Bluefish, Losartan Jubilant, Losartan Krka, Losartan Medical Valley, Losartan Mylan, Losartan Orifarm, Losartan Potassium, Losartan Ranbaxy, Losartan Sandoz, Losartan Teva, Losartan/Hydrochlorothiazide Aurobindo, Losartan/Hydrochlorothiazide Bluefish, Losartan/Hydrochlorothiazide Krka, Losartan/Hydrochlorothiazide Medical Valley, Losartan/Hydrochlorothiazide Sandoz, Losartan/Hydrochlorothiazide Teva, Losartan/Hydroklortiazid Actavis, Losartan/hydroklortiazid Jubilant, Losartan/Hydroklortiazid Orifarm, Losatrix, Losatrix comp, Losatrix Comp, Losazid Comp, Losazid Comp Forte, Lostankal, Marozid, Tanlozid

ATC code: C09CA01, C09DA01

Substances: losartan, losartan potassium


The antihypertensive effect of losartan is similar in men and women.
Losartan have comparable side effects in men and women.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

In a pharmacokinetic study, single oral and intravenous doses of losartan produced plasma concentrations of losartan that were two-fold higher in hypertensive women than in hypertensive men, due to reduced systemic clearance in women. However, plasma concentrations of the active metabolite of losartan, E 3174 (ten times more effective than the parent compound), were similar in men and women [1-4]. Even though some pharmacokinetic sex differences of losartan have been described, the clinical relevance of these has not been shown and therefore no dosage adjustment based on sex has been considered necessary [3].


A review evaluating clinical experience with losartan from worldwide, double-blind, controlled studies, confirm that the antihypertensive effect of losartan is similar in women and men [1, 3-6]. The large randomized, triple-blind LIFE study (4230 men, 4963 women) compared losartan with atenolol for reducing cardiovascular morbidity and mortality in patients, aged 55-80 years, with hypertension and left ventricular hypertrophy. Treatment effect of losartan (50 mg daily) was similar in men and women. A sex difference in the primary composite end point (cardiovascular mortality, stroke, and myocardial infarction) was observed, regardless of treatment with losartan or atenolol [7].

A clinical trial reported that women had less regression of electrocardiographic left ventricular hypertrophy than men during losartan therapy. Regression of ECG left ventricular hypertrophy is associated with improved prognosis. These findings suggest that women may derive less prognostic benefit [8].

Adverse effects

Reviews and meta-analysis consisting of several double-blind trials have reported that the overall incidence of adverse clinical events in losartan-treated patients was similar in men and women [5, 6]. In the LIFE study, women had more adverse events than men, regardless of treatment with losartan or atenolol. Serious adverse events (i.e. events causing hospitalization, prolongation of hospitalization, or death) did not differ between men and women (38.3% vs. 36.3%) [7].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2014-01-08


  1. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74:181-94. PubMed
  2. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44:797-814. PubMed
  3. Cozaar (losartan potassium). DailyMed [www]. US National Library of Medicine. [updated 2013-10-01, cited 2014-01-08]. länk
  4. Cozaar (losartan). Summary of Product Characetristics. Medical Products Agency Sweden; 2015. länk
  5. Mallion JM, Goldberg AI. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Blood Press Suppl. 1996;2:82-6. PubMed
  6. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. J Hypertens Suppl. 1995;13:S77-80. PubMed
  7. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51:1103-8. PubMed
  8. Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B et al. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy. Hypertension. 2008;52:100-6. PubMed
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson